Skip to content

Effect of erbium glass laser treatment on hair growth in patients with androgenetic alopecia

A randomized three arm pilot study evaluating efficacy and tolerability of fractional 1550 nm erbium glass laser monotherapy, erbium glass laser combined with topical minoxidil, and topical minoxidil monotherapy in androgenetic alopecia - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107839
Enrollment
45
Registered
2026-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Fractional erbium glass laser: Fractional 1550 nm erbium glass laser therapy given every 2 weeks for 24 weeks total 12 sessions. Energy 10 millijoule density 256 dots per centimeter squ

Sponsors

Krishna Institute Of Medical Sciences Karad Maharashtra India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 to 45 years with clinically diagnosed androgenetic alopecia. Male patients with Hamilton Norwood grade II to IV and female patients with Ludwig grade I to II. Patients willing to comply with study protocol and follow up

Exclusion criteria

Exclusion criteria: Patients with scarring alopecia or other hair disorders. History of laser therapy in last 6 months. Pregnant or lactating females. Patients planning pregnancy. Patients with systemic illness or drugs affecting hair growth.

Design outcomes

Primary

MeasureTime frame
Change in hair density measured by trichoscopy in hairs per centimeter squareTimepoint: Baseline, 12 weeks and 24 weeks

Secondary

MeasureTime frame
Change in hair shaft diameter diversity on trichoscopyTimepoint: Baseline, 12 weeks and 24 weeks;Global photographic assessment of hair growthTimepoint: Baseline, 12 weeks and 24 week

Countries

India

Contacts

Public ContactDr Balkrishna Nikam

Krishna Institute Of Medical Sciences, Karad

mangeshnikam@yahoo.com8275061393

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026